AH121 - Inside the DOL’s Final Rule: Transparency, Accountability, and Timelines, with Julie Selesnick

Episode 121 Q&A Highlights
- When does the final rule take effect? The rule becomes effective 60 days after publication, but it applies to plan years beginning on or after July 1, 2027.
- Does this rule apply only to PBMs? No! The new DOL rule extends to covered service providers, including anyone performing pharmacy-related services in four areas: negotiating or aggregating rebates and price concessions; maintaining formularies; maintaining pharmacy networks; or performing utilization review or management. Brokers and consultants with PBM coalitions may fall in scope, and the rule also clarifies existing 408(b)(2) obligations for medical-side TPAs, smaller plans, and fully insured plans.
- What disclosures should plan sponsors expect? Plan sponsors must receive upfront disclosures before entering, extending, or renewing a contract, with 90 days' notice for renewals and extensions. They also receive semiannual or quarterly true-up disclosures within 30 days of each period.
- What’s different about these disclosures? A lot! Every disclosure must use plain English and dollar amounts, not formulas, and must explain significant variances.
- What audit rights does the rule guarantee? Plan sponsors have the right to an audit at least once per year and can choose their own auditor without interference. Claim- and transaction-level data must be delivered within 60 days of a request, and the plan pays the auditor – importantly, confidentiality agreements can't block benchmarking.
- Will opponents challenge the rule? Julie sees litigation risk, but she does not believe that the DOL overstepped its authority.
The Road to 2027: Timelines, Triggers, and the Final DOL Rule
Nine months after a proposed rule sparked a flurry of comments, speculation, and no shortage of questions from plan sponsors, the Department of Labor's final PBM Transparency Rule landed. On this episode of Astonishing Healthcare, we Wwelcome Julie Selesnick, Executive Director of Legal and Compliance at Judi Group, back to the show for her third appearance. Julie's last appearance was in May, for Episode 106, right as the comment period on the proposed rule closed.
Episode 121 picks up where the last one left off, walking through what changed between the proposed and final versions of the rule, when it takes effect, who it covers, and what plan sponsors need to start doing right now to prepare. Selesnick, who was on stage for the official DOL announcement alongside Antonio Ciaccia, Cynthia Fisher, and Steve Ditto, brings a front-row view of both the policy details and the practical implications for newly empowered plan fiduciaries.
From Proposed to Final: What Changed?
Selesnick opens with good news for anyone who tracked the proposed rule closely:
A lot of what was in the proposed rule landed in the final rule. I am thrilled to report."
She points to new language clarifying what third-party administrators (TPAs) should be disclosing, language she sees as helpful for ERISA-covered plans trying to understand what they're entitled to receive when they request compensation disclosures or audits.
Most of the differences between the proposed and final rule, she explains, were helpful in harmoizing the DOL rule with CAA 2026, rather than to weaken it. "I like that the Department of Labor took the comments that they received seriously and did not want to create an enforcement situation where you have to do things differently under one rule than another," she says.
One notable alignment point: both CAA 2026 and the DOL rule now apply specifically to plans with at least 100 participants. Selesnick acknowledges this isn't thrilling news for smaller plans, but there's a silver lining. The final rule makes clear that smaller plans remain entitled to full compensation disclosures under existing 408(b)(2) rules, along with many of the categories specified in the new rule. The intent, she says, is "to actually spare smaller businesses from having to engage in a more cumbersome reasonableness analysis."
Timeline: When Does The New Rule Actually Take Effect?
There are nuances to the timing: The rule is effective 60 days from its publication date in early Nov..However, she's careful to correct an assumption she'd been making publicly: "I've been thinking and telling everyone it's going to be effective January 1st of 2027, but I jumped the gun." The rule will actually apply to plan years on or after July 1, 2027.
Why the gap between the effective date and the applicability date? Selesnick explains that commenters raised concerns about the lack of infrastructure to make or review these disclosures. The extra runway gives stakeholders time to develop uniform disclosure formats, gives plans time to figure out how they'll review the information, and gives third parties room to build benchmarking tools.
What Employers Should Be Doing Right Now
With the effective date on the horizon, Venneri asks the practical question: what should plan sponsors and PBMs be doing between now and then, especially given overlap with the CAA 2026 and the NCPDP D.0 to F6 transition?
Selesnick lays out a clear starting point. Plans should first look at what disclosures they're currently receiving and compare that against what they'll need to request going forward. That means rethinking the disclosure request itself and planning how the information will be reviewed once it arrives.
If an organization is running an RFP for the coming year, she's emphatic that this request needs to be built in now.
This is true comparison shopping, You can finally be able to do these things."
The goal isn't just to run a reasonableness analysis after the fact, but to use the disclosure itself as a selection criterion during the RFP process.
She also flags that fiduciaries need to think ahead about how they'll judge reasonableness, since the answer will evolve over time. A year-one reasonableness analysis will look different from a year-three or year-five analysis, simply because the benchmarking infrastructure doesn't exist yet. "It's not like you can go to this database to benchmark brand costs and figure out what's normal, because that doesn't exist yet," she explains. In the meantime, plans will need to compare categories like indirect versus direct costs, variable fees versus administrative fees, and fees versus claim costs, building their own point of reference until broader benchmarking tools catch up.
Who the DOL's New Rule Actually Covers
A common misconception, Selesnick clarifies, is thinking of this as strictly "a PBM rule." Instead, the enhanced disclosure requirement attaches to anyone performing one of four specific categories of service, regardless of whether they're a PBM, broker, consultant, or TPA:
- Negotiating or aggregating rebates, fees, discounts, or other price concessions
- Establishing or maintaining formularies
- Establishing or maintaining a pharmacy or pharmacy network
- Performing utilization review or management
This means brokers and consultants who operate purchasing coalitions or PBM coalitions, and who perform any of these functions, will also be on the hook for the enhanced disclosure. Even those who don't fall into these buckets still need to keep making their existing disclosures, and Selesnick urges plans to scrutinize those disclosures for clarity. If a broker or consultant is reporting compensation as a formula rather than a dollar figure, she recommends following up after the fact to get the actual dollar amount.
If you don't then follow up and know what that translated into in dollars, then you don't really know if it was reasonable or not."
She's particularly critical of one common response plans receive today, where brokers claim compensation like commissions or overrides is "attached to our entire book of business" and can't be tied to a specific plan. "But yes they can," she counters, pointing out that the math is knowable: figure out where in the book of business the compensation attaches, identify all the plans that contributed to reaching that threshold, and calculate a pro rata share.
For TPAs, Selesnick highlights what she calls "amazing" guidance buried in the rule.
The DOL has signaled that its next rulemaking effort will focus specifically on TPAs, acknowledging a need for more transparency on the medical management side. In the meantime, even TPAs not performing PBM-related services are required to make clearer disclosures of direct and indirect compensation, including categories like 340B-related income, provider and network compensation, affiliate and subcontractor compensation, vertically integrated compensation, and data monetization compensation. "Those are areas that no one is getting a disclosure in now," she notes, adding that Judi® (Judi) Health plans to post a template request letter on LinkedIn that plans can use to request this information.
Even fully insured plans aren't left out. Selesnick points to language in the final rule confirming these plans are entitled to a 408(b)(2) disclosure, something she says almost nobody currently receives. "I don't know anyone that's getting that. And so you should ask for that because you have to make sure it's reasonable."
Related Content
- Judi Health™ Applauds the Department of Labor for Advancing Health Plan and PBM Transparency
- Achieving Alignment with Your Pharmacy Benefits Manager
- AH064 - Empowering Plan Sponsors: Data Access & Analysis, with Bridget Mulvenna
Disclosure Timing and What Must Be Included
The rule establishes two distinct disclosure events. The first comes in advance of entering, extending, or renewing a contract, making it a natural fit for the RFP process. The second is an after-the-fact "true-up" disclosure delivered every six months, or quarterly if the plan requests it, within 30 days of the end of each period.
If there's a wide variance between the initial estimate and the true-up numbers in any category, the rule requires an explanation for that variance. Selesnick also notes that if a formula or salary change during the year is projected to result in a 5% swing in a previously disclosed figure, that change has to be reported to the plan, in advance of the change taking effect rather than after.
The content required in the upfront disclosure is extensive. For anyone performing PBM-related services, it must include a description of services being performed, an unbundled breakdown of fees (no more lumping everything under a single "Schedule A" line item), and detailed categories covering indirect compensation, manufacturer payments, rebates, alternative discounts, spread pricing, pharmacy recoupment, and pricing protection agreements. A catch-all provision requires disclosure of any new fee type that emerges in the future, regardless of what it's called.
Selesnick specifically calls out reclassification fees as something plans should request by name. This happens "when your plan and your member pays for a brand drug at the pharmacy and then afterwards it is reclassified into a generic and the pharmacy is only paid generic." She says this amount currently isn't being reported in many plans and would fall under the catch-all provision.
Full Audit Rights, Finally, in Plain English
Asked what fiduciaries should watch for in their contracts, Selesnick is direct: renegotiate audit provisions to match, at minimum, what the final rule guarantees. Under the rule, plans are entitled to audit at least once per year, with documents delivered in machine-readable files. The plan chooses its own auditor with no interference or mutual agreement requirement from the service provider. Confidentiality agreements are allowed but cannot prevent the plan from benchmarking the disclosed data against a database to assess reasonableness.
Cost responsibility is split: the plan pays for its auditor, while the PBM covers the cost of providing the required information, and cannot assist in paying for the plan's auditor. Selesnick describes this as "a fair split." What must be made available includes all records, claim and transaction-level data, and other information reasonably necessary to confirm the accuracy of disclosures, including contracts with retail pharmacies, drug manufacturers, and rebate aggregators. Plans have the right to receive this information within 60 days of making a request.
The manner of disclosure is also tightly defined. Legalese and lawyer jargon are out. Disclosures must use plain, understandable English, be clear and concise, and state monetary amounts rather than formulas. If a figure is an estimate, any variance revealed in the later true-up disclosure requires an explanation.
Industry Reaction and What Comes Next
Asked how the larger, traditional PBMs might respond, Selesnick anticipates possible legal challenges. "I think there's a risk that there's going to be a lawsuit filed," she says, noting she's already seen rumblings in various articles. She's skeptical such a challenge would succeed, pointing out that the congressional committee overseeing EBSA wrote in support of the rule and urged the department to go further, making it a difficult argument that the DOL exceeded its authority.
She also frames the rule as a deliberate bridge to the next phase of PBM regulation. It harmonizes with CAA 2026's upcoming restrictions on rebate and spread pricing, which take full effect after August 1, 2028. "It's a perfect midway step between where we are today and where we'll be after August 1, 2028," she says, giving plans the chance to understand current costs so they can evaluate the impact when those practices are no longer allowed.
Closing out the conversation, Selesnick reflects on what she finds most astonishing: how much of the proposed rule survived intact into the final version, including real transparency requirements around drug pricing methodology, paired with a promise of similar TPA-focused rules to come. She also references an industry estimate suggesting the rule could save $29 billion [Needs verification] over the next 10 years, adding, "I think it could be even more than that." Her closing message to fiduciaries is one of responsibility as much as optimism: the transparency is there, but "fiduciaries have to use this and make decisions based on what they find and make sure that they are choosing reasonable service providers."
Get in touch with our team if you'd like to learn more about our support for the new DOL rule and our transparent, aligned pharmacy benefits solutions!
Disclaimer
This podcast is for informational and entertainment purposes only. The views expressed are those of our guests, do not constitute professional advice, and may not represent Judi Health's/Capital Rx's position on any matters discussed. We make no representations or warranties regarding the accuracy or completeness of the content; information is subject to change and may not be updated.
Lightly edited for clarity.
[00:22] Justin Venneri (Host): Hello and thanks for listening to another episode of Astonishing Healthcare. This is Justin Venneri, your host, Senior Director of Communications at Judi Health. And I am so, so very excited to have Julie Selesnick back in the studio with me. For anyone who doesn't know, she's the Executive Director, Legal and Compliance at Judi Group, our independent advisory firm, and she's officially one of the foremost experts on fiduciary compliance, health benefits contracting, etc in the U.S. Julie, on episode 106, back in May, we were talking about the DOL rule and that was right at the end of the comment period. This has been an incredible year for rulemaking. There was the week that changed everything for PBMs. So that was CAA 2026, the week the DOL rule, the first FTC settlement, was announced. Here we are, roughly nine months later, the final DOL rule was published with a bang. And I want to welcome you back to the show to talk about it.
[01:10] Julie Selesnick (Guest): Thank you. And I can't believe it was just in May. I feel like you mean 20 years ago, right?
[01:16] Justin Venneri (Host): I think I gave enough about your background for context. I know this is like quick turn and we go with the whole scripted, unscripted concept at Astonishing Healthcare. So I may have a curve ball or two for you. We'll see. But it should be a fun discussion. I will put some links in the show notes for anyone that wants to learn more about your background and just some of the historical content and context here. But you've been on the show at least three times now, so I got to get you some swag.
[01:38] Julie Selesnick (Guest): I know. I feel like if this is Saturday Night Live, I'd have like a robe or jacket or something.
[01:42] Justin Venneri (Host): The DOL PBM Transparency rule announcement was - that was pretty cool. You and the one and only Antonio Ciaccia. You're up on stage with Cynthia Fisher and Steve Ditto. I think Justin Danoff was a moderator from EBSA. I never heard of EBSA before, so that was cool. Really fun to watch. And last time we talked, the rule was still proposed and the comment period just closed now. Now it's final. What's your reaction and what changed or landed in the final rule compared to what you were expecting?
[02:10] Julie Selesnick (Guest): So a lot of what was in the proposed rule landed in the final rule, I am thrilled to report. And there was even some really helpful language about sort of what TPA should be disclosing that made its way into the final rule that I think is also super helpful for ERISA covered plans knowing what they are entitled to be receiving when they ask for comp disclosures. The final rule, there's a few differences mainly made to harmonize it with language and CAA 2026. And I like that the Department of Labor took the comments that they received seriously and did not want to sort of create an enforcement situation where you have to do things differently under one rule than another. So one of the things that, you know, I wish both rules were different, but CAA 2026 and the DOL final rule now apply to plans that have at least 100 participants. And so I'm sure that is not thrilling news for smaller plans to hear, although I do think can be happy with the language that did make its way into the final rule, making clear that they're still entitled to full compensation disclosures under existing 408(B)(2)(B) rules and many of the categories specified in this final rule they're still entitled to. The goal is to actually spare smaller businesses from having to engage in a more cumbersome reasonableness analysis.
[03:31] Justin Venneri (Host): Interesting. Okay, what about the timeline here? The rule - when is it effective? When does it begin? Can you walk us through some of that?
[03:37] Julie Selesnick (Guest): Yeah. So it's effective 60 days from publication date it was published today. So I guess 60 days. I'm no math whiz, but January 1st or 2nd, however, is going to apply to plan years on or after July 1, 2027. So again, I've been thinking and telling everyone it's going to be effective January 1st of 2027. And that's. I jumped the gun a bit. It'll be effective, but not for playing years before that July 1 date. Why? Because again, a lot of the comments there were about there not being an infrastructure in place to even make these types of disclosures or to review these types of disclosures from the plan side. So this gives everyone, all stakeholders, a few months to come up with sort of uniform ways to disclose this information and for plans to figure out how they're going to review this information and hopefully for third parties to spring up with ideas on how to start benchmarking and comparing this information.
[04:36] Justin Venneri (Host): Got it. Just kind of jumping around a little bit here based on what you're saying. What should Plan sponsors and PBMs be doing between now and then? Because there are some other rules and that we - our last podcast episode focused on the NCPDP D.0 transition to F6. There's some overlap there. Like you said, CAA 2026. There's some overlap there. And I think it does seem like they're trying to take everything into consideration, which is really nice actually. But welcome your thoughts.
[05:03] Julie Selesnick (Guest): There's yeah. So the things you want to do now, if you're a plan, you want to look and see what am I getting now? For disclosures, what you're getting is definitely not what you now have to start getting. So start figuring out how am I going to ask for this? How do I want to receive this information? So what does my disclosure request look like? And then how will I review this when it comes back? If you're doing an RFP for next year, you definitely want to include this request. You know, certainly my advice would be to include it in your RFP process so that you can compare this upfront. This is true comparison shopping. You could finally be able to do these things. So you want that disclosure to be part of the RFP process so that you can make your selection, not just conduct a reasonableness analysis, but use the disclosure to actually make a selection that's going to be the most cost effective for your organization. That might not be your only consideration, but it's certainly a consideration.
The other things you want to do are figure out, okay, once we get the disclosure, how are we going to decide? We and by we, I mean whoever are the fiduciaries in charge of your plan, how are we going to decide if this is reasonable? What a year one reasonableness analysis looks like is different than what a year three or five reasonableness analysis will look like. Because year one, some of these things you're going to be comparing in a vacuum. So it's not like you can go to this database to benchmark bread costs and figure out what's normal, because that doesn't exist yet. So you're going to have to sort of be surveying what's out there that you can compare against and then figure out, okay, for these areas that I don't have anything to compare against, how am I deciding reasonableness? And it could be something like, is this what I expected to be paying? How do my indirect costs compare to my direct costs? How do my variable fees compare to my admin per month fees?
All of the categories you can think of? How did my fees compare to my claim costs? Anything you can think of? Until we build up all of the benchmarking capabilities in every area to help you conduct a thorough assessment of what you learn so that you can engage in a fiduciary process and at the end of the day decide this is reasonable or this is not reasonable.
[07:14] Justin Venneri (Host): So it sounds like a pretty darn good stake in the ground and a good starting place. Depending on Some employers I know have been a little bit more progressive over the last two to four to maybe six years, even in terms of adopting transparent models and carving things out, direct contracting, et cetera. The final rule, as you said, primarily focused on PBMs, but it included language about some other things. Can you talk about specifically what this covers for the PBMs and the affiliate brokerage and consulting providers? Does it change really that advisor and vendor relationship? And then what conflicts should sponsors look for or ask about?
[07:51] Julie Selesnick (Guest): That's a lot of questions, Justin, and one that was many. All right, let's start with the sort of broker disclosure, the broker advisor disclosure. Will it change? Maybe, maybe not. It depends. If you have the type of broker advisor that has a PBM contract, then it probably does change because they will be required to meet the more sort of extensive requirements under this new rule if they are gathering compensation in any of the ways that are outlined under the new rule. The new rule, what it does is it if you're performing services in certain areas, then you have to make this new disclosure. So it's not this is required of PBMs. It is four things that if you're doing them or four buckets where if you're acting in those buckets, then you have to make the disclosure. So it's not that you know this is a PBM rule. It is an enhanced fee disclosure for people performing specific sets of services related to PBMs and the services.
If you're acting as a negotiator or aggregator of rebates, fees, discounts, or any other price concessions, you have to make this disclosure. If you're establishing or maintaining formularies, you have to make this disclosure. If you're establishing or maintaining a pharmacy or a network of pharmacies, you have to make the enhanced disclosure. Or if you're performing utilization reviewer management, you have to make this disclosure. So that's a lot more than just PBMS making it. And particularly when it comes to brokers and consultants, many of them have these either purchasing coalitions or PBM coalitions where they do perform some of those services. So they will need to make that enhanced disclosure. However, even if they don't, they need to continue to make the disclosures they're making. And you need to make sure though, as we get more guidance in CAA and now in this final rule, there's a lot of language sort of discussing what even the existing disclosures should look like. So you want to review the rule and make sure that what you're getting meets the existing requirements, which means language you can understand dollars. And if you're getting formulas now, you want to go back after the fact and say, can you now tell me what that added up to for this year? So that the sort of a formula has been an easy peasy way to get away from this. And if you don't then follow up and know what that translated into in dollars, then you don't really know if it was reasonable or not.
There's this one answer on your broker and consultant comp disclosure that I can't stand and I think you should all stop accepting it now. It'll be required to end CAA 2026, but there's no reason to not say now this is not acceptable. Is the answer that says we may receive some compensation in the form of a commission or an override or a supplemental comp. It'll say it's attached to our entire book of business and we cannot ascribe it to any one plan. But yes they can. And so the key here is math and figuring out if it attaches at a certain point all the plans that got them to that certain point and then figuring out your pro rata share, because there are ways to quantify all of this, and that's how you determine reasonableness, is knowing the full amount. For TPAs, there's a lot of specific guidance that is amazing in the rule, actually, that tells you first, the Department of Labor makes clear that their next rule like this will focus on TPA. So, there's an understanding that medical management side TPAs, that there's a need for this, and that'll be sort of next up. Also, just to be clear, if your TPA is providing any of those PBM related services that I just mentioned, those disclosures, they have to make these. This applies to them on those grounds. But for even just a regular medical side TPA that isn't doing any of this other stuff, what the rule makes clear is that they have to make pretty good disclosures now. And those disclosures have to include direct and indirect compensation. Sort of the bonus easter egg in here was clarifying what TPAs should be producing now in response to a 408 request when they're just on the medical management side. And so this final rule makes clear that under the existing 408(B)(2)(B) disclosures, you're entitled to direct and indirect compensation, as we already know. So that includes admin fees, per employee, per month fees, 340B related income, provider and network compensation, affiliate subcontractor and vertically integrated compensation, data monetization and compensation, and payment and recovery compensation.
So 340B provider and network comp, affiliate subcontractor, vertically integrated comp, and data monetization comp. Those are areas that no one is getting a disclosure in now. So you should go ahead and we're going to post at some point on the Judi group LinkedIn a sort of template letter where you can request the disclosure. You may be supplemented with that information, because now we understand that that's what you're supposed to be getting. And so employers should get this. And this is great to be able to know this and that it's made clear in the EBSA rules so that we know that this is required. So that's going to advance the ball further than where we are now. Another sort of gem in there that was unexpected is letting small plans know, again, they're entitled to all of that as well. And if you're in a fully insured plan, there is a lot of language in the final rule that says, yeah, you're not going to get this final rule, this new rule, but you're entitled to a 408(B)(2) disclosure in a fully insured plan. I don't know anyone that's getting that. And so you should ask for that because you have to make sure it's reasonable. And so these are sort of some areas that have been filled in, been added to, or just surprisingly added to the list that now plans should go back and make sure they're getting what they're supposed to be getting throughout this process, throughout this year, throughout my process, with Lily's help and everybody else's help on my team of making this podcast work.
[13:44] Justin Venneri (Host): We've heard time and time again about the RFP process and using the RFP process to obtain these disclosures or discover this information to help you make a more informed decision. The disclosures come at contracting or renewal and then every six months with audit rights. Is that correct? And then what does a good fiduciary sort of diligence process look like? What should they pose, aside from this questionnaire you mentioned? But what do they put on their list? Like just a calendar reminder, like, hey, we have audit rights. Like, how does it, how does this work going forward?
[14:12] Julie Selesnick (Guest): That's a great another set of 10 questions in a row. It's a good question though. So first of all, there's two types of disclosures covered under this rule. The first one you get in advance of entering, extending or renewing a contract. That means that especially if you're doing an RFP, you're going to want to include this in the process. As you mentioned, every year before you're extending, renewing or entering a new one, you need to get this in advance. And you know it's up to you how far in advance you want it. The further the better, especially as you know you're sort of struggling to then do an analysis and determine its reasonableness. But that's the initial disclosure. Then under this new rule, you get these twice a year and it could be quarterly depending on it's up to the plan if they request that disclosures after the fact disclosure. So those first ones are sort of what we think is going to happen, what we anticipate. This is what we think we're going to make overall, these after the fact every six month or quarterly disclosures, they're 30 days after each six month or quarterly period you get this sort of true up disclosure that has the actual numbers. And if there is a wide variance in any category from what you were told in that initial disclosure to what actually comes out in that true up disclosure, there has to be an explanation as to why that happened and why there is such a variance. Also, if at any point during the year a formula change is going to result in a five percent change in a disclosure that was made to you that has to be reported to you within 30 days.
So, there's a lot of fascinating things and I don't even think I've said yet what you have to disclose here in this upfront disclosure before signing, renewing, extending for the under this new rule, if you're performing any of those services that we discussed related to PBMs, first a description of the services of what, what you're going to be doing that sort of sets the expectations and lets fiduciaries know what they're supposed to monitoring. And by the way, if you're used to getting a sort of schedule A that lists a PEP and then 30 services under it, they have to be unbundled so you can see what's worth what to add up to that fee, by the way, 90 days in advance for extensions or renewals. So the upfront one, it's up to you. But if you're extending or renewing 90 days in advance. Then you've got indirect comp, manufacturer payments, rebates, alternative discounts, any other remuneration spread pricing, pharmacy recoupment, pricing protection agreements. And then there's a catch all, and that's to catch all of the fees that are going to pop up that don't exist today, but that are going to sort of replace these categories.
Going forward, anything at all, if it is a fee and it is going either directly to your service provider or indirectly from a manufacturer or rebate anybody to that service provider, it doesn't matter what it's called, it has to be disclosed to you. And that would include something that we talked about the last time I was here, which would be that reclassification type of fees. And I would specifically ask for those. And that, just so everyone to remind everyone, that is when your plan and your member pays for a brand drug at the pharmacy and then afterwards it is reclassified into a generic and the pharmacy is only paid generic that amount currently. I don't know if it's getting reported at all in many plans and so specifically request that. And that would fall under the catch all provision. Then you have to have a description of any compensation related to termination, which is great because that's like a penalty for terminating a little bit of an anti competitive type of provision. And sometimes people lose their rebates, lose performance guarantees. So that would have to be described there because that would become compensation if you lose it. Formulary placement incentives.
And again, advance notice if there's going to be a modification to the formulary that has a material impact on the reasonableness. I misspoke when I said it has to be made within 30 days of the change. It has to be made in advance of making that change. And then drug pricing methodology, this is another like awesome thing that I wasn't sure was going to make it into the final. And that includes net price per course of treatment for each drug on the formulary. And actually in the preamble to the final rule, there is a nod to sort of net effective cost. It's sort of simple bid comparison disclosure where you know, after you zero out everything, what is the cost of this drug? And then a statement of your fiduciary status and a statement of audit rights.
[18:34] Justin Venneri (Host): So that leads us into the next question, what are the audit rights and what do you need to make sure that you're not giving away in your contracts?
[18:42] Julie Selesnick (Guest): So when you're renegotiating your contracts, you want to change the audit provisions. At a minimum to say you will have all the audit rights that are guaranteed under this final rule. And then potentially more specifically, depending on if you have a lawyer negotiating for you or if you want to get into the nitty gritty. But this says you're entitled to audit at least once per year. That if you request test the documents and machine readable files, that's how they have to be given to you. The plan picks the auditor of their choosing with zero interference, no mutual agreement required, nothing like that. There can be a confidentiality agreement so that what is provided isn't redisclosed. But that confidentiality agreement cannot prevent benchmarking these against a database where these are put so that you can assess reasonableness. In that way, the plan pays for the auditor. PBM cannot assist with paying the auditor, but the PBM does pay for the cost of providing the required information to you. So it's sort of, I think, a fair split. And what has to be made available is all records, claim and transaction level data, and any other information that's reasonably necessary to confirm the accuracy of the disclosures. That includes contracts with retail pharmacies, drug manufacturers, rebate aggregates, that's it. And again, reasonable confidentiality agreements are allowed, but that means that they cannot preclude the ability to use that for benchmarking, to add it to a database so that you can benchmark it. And any request for audit, you have to get this information within 60 days of when the request is made. So renegotiate your contracts to match those terms.
[20:18] Justin Venneri (Host): That's incredible. In a way. Addresses. It's kind of funny. Antonio had a couple of gems during the panel. You had some good ones too. But his was like, you can't manage what you can't measure.
[20:33] Julie Selesnick (Guest): And he's right, you can't measure what you don't know or whatever it is he said that I'm sure was much smarter than what I just said. But so remember, once you get your disclosures, that's a good thing to keep thinking is, do I know what this means? Can I understand this? And that actually brings me into another good point, that the manner of disclosure is really set out in the rule. Can't use legalese and, you know, lawyer jargon. So that's great for people. It has to be in plain, understandable English. It has to be clear and concise. There has to be monetary amounts, no formulas allowed, dollars. And if it's an estimate, again, when you do those true up disclosures, if there's a variance from the estimate there should be an explanation as to why. Confidentiality agreement. It's allowed, but the PBM cannot restrict how the plan uses the disclosures. They can be shared with auditors, consultants and attorneys to benchmark and renegotiate the rules. Specifically contemplate sort of third party service providers and teams, tech providers, coming up with these sort of benchmarking tools.
[21:31] Justin Venneri (Host): Yeah, it's pretty impressive in terms of the, the list of what's included this time around and what needs to be done. And it, it does go to that, that catch all is kind of like the, the quote, the rowdy, Rowdy Piper quote, right? Like, well, now you can't really change the question because anything new, that's a fee, you've got to include that.
All right, so two more quick questions for you. Enforcement risk. How do you expect the big three kind of traditional PBMs or anybody that opposes this to respond to? Is it really just, hey, this is cumbersome, it's going to be a burden cost associated with it kind of thing, or do you see any other delay or implementation risk?
[22:05] Julie Selesnick (Guest): I think there's a risk that there's going to be a lawsuit filed. I think I've already sort of heard some rumblings and seen this written in various articles that they could challenge this in a lawsuit. I think that is a waste of money and effort. I don't think the department has overstepped what it was authorized to do here. And in fact, fact, any argument to that is sort of belied by the fact that the congressional committee that oversees EPSA wrote in support of this rule and urged them to go further. So I think it's a tough argument to say that they exceeded what Congress wanted them to do. I also think it's harmonized with CAA 2026, especially when it comes to rebate and spread. It's a perfect midway step between where we are today and where we'll be after August 1, 2028, when those things aren't allowed anymore. Plans have to know what it's costing them, can understand what they should be looking at for cost shifts starting at that point when it's not allowed anymore. Because there are going to be a lot of changes in pricing and it's going to be very helpful to understand what you're paying now and what is being withheld now. And there's lots of other categories there that aren't going away in CAA 2026 and that this is exactly what the Department of Labor is supposed to be doing is overseeing that fiduciaries are overseeing their service providers and giving them the tools to do, do that.
[23:20] Justin Venneri (Host): And last one, have to ask the most astonishing thing about everything we're talking about today and everything that's been going on that's safe to share, of course. Tell us what's most astonishing to you. Close us out here today.
[23:30] Julie Selesnick (Guest): I think what's most astonishing to me is how much of the proposed rule made it through to the final that we're going to get real transparency on things like drug pricing methodology. And we have a promise that sort of similar rules for TPAs are coming next. And until then we've still been given amazing language to sort of advance the ball now and increase transparency and accountability with other service providers. So I just couldn't be more pleased with this rule. May it continue. May all the things that are coming next come next and we're really set up for transparency is great, but now fiduciaries have to use this and make decisions based on what they find and make sure that they are choosing reasonable service providers. And I do think that we're going to save. I think that the estimates that EPSA did suggested $29 billion from this rule will be saved over the next 10 years. That's good money. I think it could be even more than that and I'm really excited to see these go into action.
[24:24] Justin Venneri (Host): Likewise. Well, Julie, thank you so much for taking the time. Always appreciated. And look forward to staying in touch, hopefully having you back on.
[24:30] Julie Selesnick (Guest): Thank you. See you soon.
.webp)



.webp)

.png)